EXVADE BIOSCIENCE INC

Atlanta, GA · Medtech · Private

Tumor Monorail, an implantable device for serial real-time access to glioblastoma tissue for monitoring tumor progression and treatment response

Grants
$2.8M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Tumor Monorail Device for Serial Glioblastoma Biopsy$399,217
Federal grantDepartment of Health and Human Services · Phase I · Tumor Monorail Device for Serial Glioblastoma Biopsy$399,217
Federal grantDepartment of Health and Human Services · Phase II · Tumor Monorail Device for Serial Glioblastoma Biopsy$999,360
Federal grantDepartment of Health and Human Services · Phase II · Tumor Monorail Device for Serial Glioblastoma Biopsy$999,038
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2097InseRT——
2098Monogram Orthopaedics Inc.——
2099GEL4MED, INC.——
2100EXVADE BIOSCIENCE INC——
2101NEUROFIELDZ INC.——
2102AI Viewlife——
2103Phase One Medical, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Tumor Access Devices With Integrated Sensorsapplication
  • Tumor Access Device With Integrated Sensorapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.